Top 5 Stocks to Buy Now
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free DRMAW Stock Alerts

Dermata Therapeutics (DRMAW) Competitors

Dermata Therapeutics logo
$0.01 0.00 (0.00%)
As of 06/23/2026 03:17 PM Eastern
Compare

DRMAW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy Dermata Therapeutics stock or one of its competitors? MarketBeat compares Dermata Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dermata Therapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does Dermata Therapeutics compare to Ainos?

Ainos (NASDAQ:AIMDW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, dividends, risk, earnings, valuation and institutional ownership.

Company Net Margins Return on Equity Return on Assets
AinosN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

In the previous week, Ainos' average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Overall Sentiment
Ainos Neutral
Dermata Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Ainos$18.11KN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Summary

Ainos beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Dermata Therapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and Dermata Therapeutics (NASDAQ:DRMAW) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

In the previous week, Alvotech's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Overall Sentiment
Alvotech Neutral
Dermata Therapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

Summary

Alvotech beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks.

How does Dermata Therapeutics compare to Aravive?

Dermata Therapeutics (NASDAQ:DRMAW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends and institutional ownership.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled Aravive'saverage media sentiment score.

Company Overall Sentiment
Dermata Therapeutics Neutral
Aravive Neutral

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Aravive beats Dermata Therapeutics on 2 of the 2 factors compared between the two stocks.

How does Dermata Therapeutics compare to Atlantic Coastal Acquisition Corp. II?

Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) and Dermata Therapeutics (NASDAQ:DRMAW) are both pharmaceutical products companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, analyst recommendations, media sentiment, institutional ownership, earnings and risk.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A
Dermata TherapeuticsN/AN/AN/AN/AN/A

In the previous week, Atlantic Coastal Acquisition Corp. II's average media sentiment score of 0.00 equaled Dermata Therapeutics'average media sentiment score.

Company Overall Sentiment
Atlantic Coastal Acquisition Corp. II Neutral
Dermata Therapeutics Neutral

Company Net Margins Return on Equity Return on Assets
Atlantic Coastal Acquisition Corp. IIN/A N/A N/A
Dermata Therapeutics N/A N/A N/A

Summary

Atlantic Coastal Acquisition Corp. II and Dermata Therapeutics tied by winning 0 of the 0 factors compared between the two stocks.

How does Dermata Therapeutics compare to Biofrontera?

Dermata Therapeutics (NASDAQ:DRMAW) and Biofrontera (NASDAQ:BFRIW) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

In the previous week, Dermata Therapeutics' average media sentiment score of 0.00 equaled Biofrontera'saverage media sentiment score.

Company Overall Sentiment
Dermata Therapeutics Neutral
Biofrontera Neutral

Company Net Margins Return on Equity Return on Assets
Dermata TherapeuticsN/A N/A N/A
Biofrontera N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dermata TherapeuticsN/AN/AN/AN/AN/A
Biofrontera$43.20MN/AN/AN/AN/A

Summary

Biofrontera beats Dermata Therapeutics on 1 of the 1 factors compared between the two stocks.

Get Dermata Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for DRMAW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DRMAW vs. The Competition

Export
MetricDermata TherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$465.85M$6.44B$12.38B
Dividend YieldN/A3.86%2.69%5.83%
P/E RatioN/A3.1824.6723.99
Price / SalesN/A6,495.10528.41106.93
Price / CashN/A13.1344.8254.51
Price / BookN/A90.8210.766.50
Net IncomeN/A-$96.07M$3.56B$336.88M
7 Day PerformanceN/A1.22%1.03%-0.14%
1 Month PerformanceN/A0.81%0.45%0.77%
1 Year PerformanceN/A64.35%29.69%28.49%

Dermata Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DRMAW
Dermata Therapeutics
N/A$0.01
flat		N/A-36.7%$0.00N/AN/A8
AIMDW
Ainos
N/A$0.14
-0.4%		N/A-21.8%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.25
flat		N/A-85.5%$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/A-90.5%$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:DRMAW) was last updated on 6/24/2026 by MarketBeat.com Staff.
From Our Partners
My feud with Zohran Mamdani
Nearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...
Stansberry Research | Sponsoredtc pixel
Quick favor to ask you
Bill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...
Profits Run | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Top Banks Warn: A Strange Day is Coming to America
Goldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...
TradeSmith | Sponsoredtc pixel
A drilling crew just broke a record nobody expected
A drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...
Behind the Markets | Sponsoredtc pixel
Millionaire trader who went 13-for-13 on Trump in 2025 now turns his attention to Elon.
Hedge fund trader Larry Benedict went 13-for-13 in Q1 2025 - not a single losing trade - and finished the year...
Brownstone Research | Sponsoredtc pixel
Karp just filed Form 144
On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...
Porter & Company | Sponsoredtc pixel